AstraZeneca unbranded effort urges sufferers to "Rethink COPD"

Share this article:
AstraZeneca unbranded effort urges sufferers to "Rethink COPD"
AstraZeneca unbranded effort urges sufferers to "Rethink COPD"
AstraZeneca is rolling out an unbranded COPD education campaign featuring comedian and actor Robert Klein.

The campaign, dubbed RethinkCOPD, is aimed at getting sufferers to consider their options with respect to diet, exercise and, of course, medication.

“For a lot of these patients, it's really about getting through their day,” said senior brand communications manager Dana Settembrino. “It's a struggle to get out of bed in the morning, it's a struggle to brush their teeth, and they want to be independent. It's all about getting them to talk to their doctor and start to think differently about this condition. There's not a lot known about it, and there's a stigma associated with it because most people have gotten it from smoking.”

Klein, a 67-year-old Bronx-born performer whose career has spanned Broadway roles and HBO comedy specials, features on the campaign's website (www.RethinkCOPD.com), where he'll discuss his diagnosis and the steps he's taken to keep his COPD in check. The campaign also features 15-second broadcast PSAs aimed at driving traffic to the Website.

The tagline of the aspirational campaign is “People with COPD are expecting more.” AstraZeneca worked with agencies Edelman, Cadient and Digitas Health on it.

The company's Symbicort, indicated for COPD as well as asthma, is not mentioned in the effort.
Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?